Price
$14.97+36.46%Social Signal Score
Analyst Ratings
15 analysts52-week range
- Last close
- $14.97
- Off 52w high
- -1.8%
- 200-day average
- $8.14
- vs 200-day
- +83.9%
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sushil Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 465
- Beta
- 0.93
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.03
Financials
Net Income
$-57.12MEBITDA
$-53.32MFree Cash Flow
$-47.78MEPS (diluted)
$-0.54Shares Outstanding (diluted)
105.18M+241.1%Operating Expenses
$56.28MCash & Debt
$307.83MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-313.94M | $-3.38 |
| 2025 | $0.00 | $-247.30M | $-3.07 |
| 2024 | $0.00 | $-215.79M | $-3.24 |
| 2023 | $0.00 | $-174.28M | $-2.99 |
| 2022 | $0.00 | $-118.04M | $-2.26 |
| 2021 | $0.00 | $-80.87M | $-1.75 |
| 2020 | $0.00 | $-52.63M | $-1.54 |
| 2019 | $0.00 | $-30.83M | $-1.33 |
| 2018 | $0.00 | $-19.70M | $-0.64 |
| 2017 | $0.00 | $-7.70M | $-0.36 |
Valuation
REPLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+100.00%Social Signal Score
Mentions (14)
- Newszacks.com·4d ago·Neutral
Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet The consensus price target hints at a 29.5% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·20d ago·Positive
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsfool.com·25d ago·Positive
Replimune: 3 Key Takeaways for Long-Term Investors Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - …
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
…econd Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live
View source ↗ - Newsseekingalpha.com·68d ago·Neutral
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·89d ago·Negative
REPL Stockholders Have Rights – If You Lost Money Investing in Replimune Group, Inc. Contact Robbins LLP for Information About Recovering Your Losses Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company's Chief Commercial Officer.
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
…ted financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.
View source ↗ - Newszacks.com·104d ago·Positive
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
View source ↗ - Newsbusinesswire.com·104d ago·Neutral
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL LOS ANGELES--(BUSINESS WIRE)---- $REPL--Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL.
View source ↗ - Newsbusinesswire.com·107d ago·Negative
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $REPL--REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $-0.56 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$-0.54 vs $-0.78beat
- Fri, Aug 14$-0.72 vs $-0.69miss
- Mon, Jun 29$-0.76 vs $-0.73miss
- Tue, Feb 3$-0.77 vs $-0.77miss
- Thu, Nov 6$-0.90 vs $-0.87miss
- Thu, Aug 7$-0.95 vs $-0.83miss
Estimates and results for REPL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by REPL officers and directors.
- Bought
- $274
- Sold
- $5.4m
2 trades
37 trades
- Xynos Konstantinossold
- Schwendenman Andrewsold
- Patel Sushilsold
- Hill Emily Luisasold
- Slattery Joseph Psold
- Dhingra Kapilsold
- Hill Emily Luisasold
- Baker Bros. Advisors Lpbought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in REPL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
